FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379328517> ?p ?o ?g. }

• W4379328517 endingPage "TPS1116" @default.
• W4379328517 startingPage "TPS1116" @default.
• W4379328517 abstract "TPS1116 Background: Overexpression of the HER2 protein is an important prognostic and predictive biomarker in about 20% of breast cancers, and while trastuzumab-based regimens are still considered standard of care in the early and metastatic settings, these regimens require chemotherapy co-administration. Pre-clinical mouse models suggest that a tucatinib/CDK 4/6 inhibitor combination regimen may be equally effective as standard regimens. Thus, finding more effective/tolerable therapies for this disease remains an area of unmet need. This randomized, open label, phase II clinical trial will explore the safety and efficacy of two novel, chemotherapy free combination drug regimens, given neoadjuvantly, in patients with anatomic stage I-III, HER2+ breast cancer. Methods: Phase 1b dose escalation trial: To establish the safety profile of the combination of ribociclib and tucatinib, an initial dose-finding phase 1b trial will be performed in patients with metastatic HER2+ breast cancer before moving into the larger phase 2 trial. 3-6 patients will be assigned sequentially to groups of increasing doses of ribociclib (200mg-600 mg) with fixed doses of tucatinib (300mg) and trastuzumab (SOC dosing) for a total of four 28-day cycles. The recommended phase 2 dose will be established when 6 patients have been treated at the highest dose level cohort. As of January 2023, 1 participant has been enrolled in dose level 1. Phase 2 neoadjuvant trial: Following MTD determination and approval from regulatory boards and funding partners, a total of 100 patients will be enrolled in the phase 2 portion of the study. Enrollment will be stratified by hormone receptor status. Patients will be randomized 1:1 (25 in each group) to receive six cycles of one of the following regimens: ribociclib/trastuzumab/tucatinib/+/- fulvestrant (28 day cycles) or docetaxel/carboplatin/trastuzumab/pertuzumab (SOC, 21 day cycles), preceded by one run-in cycle of trastuzumab/pertuzumab. To assess for changes in predictive molecular biomarkers, biopsies pre-and-post cycle 1 will be planned in all arms. Early imaging response assessments in the experimental arms will be planned after 2 cycles. Other endpoints include safety, changes in Ki67 expression, RCBi, biomarker analysis, and health-related quality of life. Clinical trial information: NCT05319873 ." @default.
• W4379328517 created "2023-06-05" @default.
• W4379328517 creator A5010783560 @default.
• W4379328517 creator A5015491002 @default.
• W4379328517 creator A5038786944 @default.
• W4379328517 creator A5047005057 @default.
• W4379328517 creator A5068059897 @default.
• W4379328517 creator A5088539775 @default.
• W4379328517 date "2023-06-01" @default.
• W4379328517 modified "2023-09-25" @default.
• W4379328517 title "UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast cancer." @default.
• W4379328517 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.tps1116" @default.
• W4379328517 hasPublicationYear "2023" @default.
• W4379328517 type Work @default.
• W4379328517 citedByCount "0" @default.
• W4379328517 crossrefType "journal-article" @default.
• W4379328517 hasAuthorship W4379328517A5010783560 @default.
• W4379328517 hasAuthorship W4379328517A5015491002 @default.
• W4379328517 hasAuthorship W4379328517A5038786944 @default.
• W4379328517 hasAuthorship W4379328517A5047005057 @default.
• W4379328517 hasAuthorship W4379328517A5068059897 @default.
• W4379328517 hasAuthorship W4379328517A5088539775 @default.
• W4379328517 hasConcept C121608353 @default.
• W4379328517 hasConcept C126322002 @default.
• W4379328517 hasConcept C143998085 @default.
• W4379328517 hasConcept C203092338 @default.
• W4379328517 hasConcept C2775930923 @default.
• W4379328517 hasConcept C2778336483 @default.
• W4379328517 hasConcept C2779786085 @default.
• W4379328517 hasConcept C2781413609 @default.
• W4379328517 hasConcept C31760486 @default.
• W4379328517 hasConcept C530470458 @default.
• W4379328517 hasConcept C535046627 @default.
• W4379328517 hasConcept C71924100 @default.
• W4379328517 hasConceptScore W4379328517C121608353 @default.
• W4379328517 hasConceptScore W4379328517C126322002 @default.
• W4379328517 hasConceptScore W4379328517C143998085 @default.
• W4379328517 hasConceptScore W4379328517C203092338 @default.
• W4379328517 hasConceptScore W4379328517C2775930923 @default.
• W4379328517 hasConceptScore W4379328517C2778336483 @default.
• W4379328517 hasConceptScore W4379328517C2779786085 @default.
• W4379328517 hasConceptScore W4379328517C2781413609 @default.
• W4379328517 hasConceptScore W4379328517C31760486 @default.
• W4379328517 hasConceptScore W4379328517C530470458 @default.
• W4379328517 hasConceptScore W4379328517C535046627 @default.
• W4379328517 hasConceptScore W4379328517C71924100 @default.
• W4379328517 hasIssue "16_suppl" @default.
• W4379328517 hasLocation W43793285171 @default.
• W4379328517 hasOpenAccess W4379328517 @default.
• W4379328517 hasPrimaryLocation W43793285171 @default.
• W4379328517 hasRelatedWork W1972234726 @default.
• W4379328517 hasRelatedWork W2040689610 @default.
• W4379328517 hasRelatedWork W2066747782 @default.
• W4379328517 hasRelatedWork W2401765432 @default.
• W4379328517 hasRelatedWork W2441572282 @default.
• W4379328517 hasRelatedWork W2604148568 @default.
• W4379328517 hasRelatedWork W2883732412 @default.
• W4379328517 hasRelatedWork W3207233484 @default.
• W4379328517 hasRelatedWork W4229078654 @default.
• W4379328517 hasRelatedWork W4304690509 @default.
• W4379328517 hasVolume "41" @default.
• W4379328517 isParatext "false" @default.
• W4379328517 isRetracted "false" @default.
• W4379328517 workType "article" @default.